内容紹介
Long-Term Survival in a Case of Recurrent Gastrointestinal Stromal Tumor Treated with Intermittent or Low-Dose Imatinib
Summary
A 65-year-old woman with a gastrointestinal stromal tumor(GIST)underwent a total gastrectomy in 1999. In 2004, she was diagnosed with an intra-abdominal recurrence and was treated with 300 mg/day of imatinib. Because of the side effects of imatinib, we interrupted the treatment and were forced to reduce the dose from 300 mg/day to 100 mg/day. However, at present, the tumor remains controlled. In conclusion, this case suggested that, even if given irregularly or at a low-dose, continuous treatment with imatinib might contribute to long-term survival in patients with GIST.
要旨 症例は65歳,女性。胃gastrointestinal stromal tumor(GIST)に対して胃全摘術を施行後,腹腔内再発を来したためimatinib 300 mg/dayの投与を開始した。以降,有害事象により二度の中断と100 mg/dayまでの減量を余儀なくされ,不定期な通院を繰り返している。中断時には腫瘍は増大するものの再開中は腫瘍の縮小を認め,病勢コントロールを得たまま外来加療中である。間欠的・低用量投与であっても,imatinibはGIST長期生存に寄与する可能性が示唆された。
目次
Summary
A 65-year-old woman with a gastrointestinal stromal tumor(GIST)underwent a total gastrectomy in 1999. In 2004, she was diagnosed with an intra-abdominal recurrence and was treated with 300 mg/day of imatinib. Because of the side effects of imatinib, we interrupted the treatment and were forced to reduce the dose from 300 mg/day to 100 mg/day. However, at present, the tumor remains controlled. In conclusion, this case suggested that, even if given irregularly or at a low-dose, continuous treatment with imatinib might contribute to long-term survival in patients with GIST.
要旨 症例は65歳,女性。胃gastrointestinal stromal tumor(GIST)に対して胃全摘術を施行後,腹腔内再発を来したためimatinib 300 mg/dayの投与を開始した。以降,有害事象により二度の中断と100 mg/dayまでの減量を余儀なくされ,不定期な通院を繰り返している。中断時には腫瘍は増大するものの再開中は腫瘍の縮小を認め,病勢コントロールを得たまま外来加療中である。間欠的・低用量投与であっても,imatinibはGIST長期生存に寄与する可能性が示唆された。